New York, New York (PRWEB) January 12, 2013
Fresenius Medical Care, the maker of GranuFlo and NaturaLyte dialysis products, supports the consolidation of all federally-filed GranuFlo lawsuits in a multidistrict litigation in U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. In a brief filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) on January 3rd, the company said it is facing 37 federal claims filed in various jurisdictions involving allegations that GranuFlo and NaturaLyte caused plaintiffs to suffer serious cardiopulmonary injuries. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428 (JPML))
“GranuFlo and NaturaLyte were administered to thousands of dialysis patients. Because this has the potential to become a large litigation, we agree that consolidation of the claims in a single court is appropriate,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to victims of cardiac arrest, heart attacks, stroke, sudden cardiac death, or other serious heart problems allegedly caused by GranuFlo and NaturaLyte.
GranuFlo and NaturaLyte are used during dialysis to reduce the amount of acid in the blood. In March 2012, Fresenius issued an “Urgent Product Notification” to its customer clinics warning of possible heart risks associated with the products. According to the notice, both have the potential to cause a rapid and unsafe elevation of bicarbonate, which creates a substantially increased risk of cardiopulmonary arrest and death. The U.S. Food & Drug Administration (FDA) would later deem Fresenius’ notification a Class I recall, its most urgent type o
Copyright©2012 Vocus, Inc.
All rights reserved